about
Development of a new diabetes medication self-efficacy scale and its association with both reported problems in using diabetes medications and self-reported adherenceOnline medical care: the current state of "eVisits" in acute primary care delivery.Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa-infected patients.Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.The electronic medication complete communication (EMC2) study: Rationale and methods for a randomized controlled trial of a strategy to promote medication safety in ambulatory care.Changes in Statin Adherence Following an Acute Myocardial Infarction Among Older Adults: Patient Predictors and the Association With Follow-Up With Primary Care Providers and/or Cardiologists.Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.Adherence Tradeoff to Multiple Preventive Therapies and All-Cause Mortality After Acute Myocardial Infarction.Review of methodological challenges in comparing the effectiveness of neoadjuvant chemotherapy versus primary debulking surgery for advanced ovarian cancer in the United StatesIt's Not Too Late to Improve Statin Adherence: Association Between Changes in Statin Adherence from Before to After Acute Myocardial Infarction and All-Cause MortalityImplications of Removing Rosiglitazone's Black Box Warning and Restricted Access Program on the Uptake of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors Among Patients with Type 2 DiabetesOpening the black box of the group-based trajectory modeling process to analyze medication adherence patterns: An example using real-world statin adherence dataEvaluation of a pharmaceutical assessment screening tool to measure patient acuity and prioritise pharmaceutical care in a UK hospital
P50
Q37007304-F6424493-B04A-4B18-943B-2B5615F9A7F5Q38282985-C7ACD57E-3CB7-4E76-B02F-241D421D397FQ40467419-35495832-A087-4411-A70E-8B0C97CE7986Q40687385-B18FF36F-6E28-4F4A-90FF-6F0081687A03Q42744765-A6D8A3F4-FE1D-46BE-A94A-2FC3DAD1878CQ47157796-4F6875F8-D6D7-4E43-ABE5-29E984B704D3Q47741739-26F3FD98-A164-4969-B525-6BD2C80D9541Q49958779-D35F8526-124C-4C3A-B827-47B2A4C96670Q57171698-77FDD88C-CD08-40A5-BDE8-38A60786E2FBQ64100028-B61D4FEF-8F7F-48BB-A12E-7D5633719C94Q64272880-3A11DFE5-CB2A-49AF-AA56-C69AD238EE5EQ91703250-B0F43742-363F-43D0-914E-9E5C6602968DQ92480538-41DA1ABB-3342-45D5-8AE6-6884F93E9381
P50
description
researcher
@en
wetenschapper
@nl
name
Ryan P Hickson
@en
Ryan P Hickson
@nl
type
label
Ryan P Hickson
@en
Ryan P Hickson
@nl
prefLabel
Ryan P Hickson
@en
Ryan P Hickson
@nl
P31
P496
0000-0002-3448-589X